Vivalink Announces World’s First Multi-Vital Blood Pressure Patch for Remote Patient Monitoring

Vivalink, a leading provider of digital healthcare solutions, announces availability of the world’s first multi-vital blood pressure patch for remote patient monitoring for use in commercial research and development.

The advanced multimodal continuous signal processing patch uses electrical signal-based technologies to capture ECG trace, heart rate, respiratory rate, systolic and diastolic blood pressure on a single device. The device is FDA/NMPA cleared for ECG and heart rate, and CE cleared for ECG, heart rate and respiratory rate. The blood pressure feature is integrated and available for research and development. Weighing just 7.5 grams and the size of a small bandage, the reusable and rechargeable wearable patch requires no additional components such as a wristband or wires in order to capture blood pressure.

Designed for remote and ambulatory patient monitoring such as hypertension diagnosis and management, the patch is wireless network enabled to automatically capture and send a continuous stream of data to clinical applications in the cloud. In addition, the patch contains on-board memory in order to capture data during network outages, and then automatically synchronize the data once network connections are re-established.

Key benefits of the blood pressure feature include automated readings of systolic and diastolic pressure. The water-resistant patch can be worn inconspicuously throughout the day to capture blood pressure and other key vitals in remote settings and during sleep. Validation of the blood pressure capability was conducted in accordance with ISO 81060-2 standards over a range of physiological profiles.

Development of the advanced blood pressure algorithm is enabled by the use of Vivalink’s Biometrics Data Platform which is uniquely designed to provide uninterrupted streams of real-world physiological data for AI development. Other advanced algorithms in development using the Biometrics Data Platform include cardiac mechanics and hemodynamics.

“We pride ourselves in continuous innovation,” said Jiang Li, CEO at Vivalink. “This milestone further establishes Vivalink as a leader and innovator in the remote patient monitoring market.”

The multi-vital blood pressure patch is available now for commercial research and development.

SourceVivalink

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”